Loading...
PREDICTIVE AND PROGNOSTIC ANGIOGENIC MARKERS IN A GYNECOLOGIC ONCOLOGY GROUP PHASE II TRIAL OF BEVACIZUMAB IN RECURRENT AND PERSISTENT OVARIAN OR PERITONEAL CANCER
OBJECTIVE: Potential predictive/prognostic angiogenic markers were prospectively examined in a phase II trial of bevacizumab in epithelial ovarian cancer (EOC)/primary peritoneal cancer (PPC). METHODS: Recurrent/persistent EOC/PPC patients were treated with bevacizumab (15mg/kg IV q21days) until dis...
Na minha lista:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2010
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2975758/ https://ncbi.nlm.nih.gov/pubmed/20870280 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2010.08.016 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|